These findings underscore CK2B as a promising target for overcoming the exhaustion of effector CD8+ T cells, thereby enhancing the efficacy of anti‐PD‐1 and adoptive cell therapies in NSCLC. This evidence concerns the gene CSNK2B and non-small cell lung carcinoma.